These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 27406919)

  • 1. A position statement on the management of patients with pityriasis rosea.
    Chuh A; Zawar V; Sciallis G; Kempf W
    J Eur Acad Dermatol Venereol; 2016 Oct; 30(10):1670-1681. PubMed ID: 27406919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study of effectiveness of oral acyclovir with oral erythromycin in the treatment of Pityriasis rosea.
    Amatya A; Rajouria EA; Karn DK
    Kathmandu Univ Med J (KUMJ); 2012; 10(37):57-61. PubMed ID: 22971864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acyclovir is not effective in pityriasis rosea: Results of a randomized, triple-blind, placebo-controlled trial.
    Singh S; ; Tiwary NK
    Indian J Dermatol Venereol Leprol; 2016; 82(5):505-9. PubMed ID: 27212277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of oral acyclovir during early course of pityriasis rosea: a systematic review and meta-analysis.
    Chang HC; Sung CW; Lin MH
    J Dermatolog Treat; 2019 May; 30(3):288-293. PubMed ID: 30109959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of high-dose acyclovir in pityriasis rosea.
    Drago F; Vecchio F; Rebora A
    J Am Acad Dermatol; 2006 Jan; 54(1):82-5. PubMed ID: 16384760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low dose of acyclovir may be an effective treatment against pityriasis rosea: a random investigator-blind clinical trial on 64 patients.
    Rassai S; Feily A; Sina N; Abtahian S
    J Eur Acad Dermatol Venereol; 2011 Jan; 25(1):24-6. PubMed ID: 20477925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pityriasis Rosea: An Updated Review.
    Leung AKC; Lam JM; Leong KF; Hon KL
    Curr Pediatr Rev; 2021; 17(3):201-211. PubMed ID: 32964824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of acyclovir in the treatment of pityriasis rosea. A systematic review and meta-analysis.
    Rodriguez-Zuniga M; Torres N; Garcia-Perdomo H
    An Bras Dermatol; 2018; 93(5):686-695. PubMed ID: 30156618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The comparison between the efficacy of high dose acyclovir and erythromycin on the period and signs of pitiriasis rosea.
    Ehsani A; Esmaily N; Noormohammadpour P; Toosi S; Hosseinpour A; Hosseini M; Sayanjali S
    Indian J Dermatol; 2010; 55(3):246-8. PubMed ID: 21063515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Azithromycin does not cure pityriasis rosea.
    Amer A; Fischer H
    Pediatrics; 2006 May; 117(5):1702-5. PubMed ID: 16651327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized, Double-blind, Placebo-Controlled Study of Efficacy of Oral Acyclovir in the Treatment of Pityriasis Rosea.
    Ganguly S
    J Clin Diagn Res; 2014 May; 8(5):YC01-4. PubMed ID: 24995231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of azithromycin in pityriasis rosea: a randomized, double-blind, placebo-controlled trial.
    Pandhi D; Singal A; Verma P; Sharma R
    Indian J Dermatol Venereol Leprol; 2014; 80(1):36-40. PubMed ID: 24448121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind randomized placebo-controlled trial to evaluate the efficacy and safety of short-course low-dose oral prednisolone in pityriasis rosea.
    Sonthalia S; Kumar A; Zawar V; Priya A; Yadav P; Srivastava S; Gupta A
    J Dermatolog Treat; 2018 Sep; 29(6):617-622. PubMed ID: 29363373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acyclovir in pityriasis rosea: An observer-blind, randomized controlled trial of effectiveness, safety and tolerability.
    Das A; Sil A; Das NK; Roy K; Das AK; Bandyopadhyay D
    Indian Dermatol Online J; 2015; 6(3):181-4. PubMed ID: 26009712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antivirals for pityriasis rosae.
    Castanedo-Cazares JP; Lepe V; Moncada B
    Photodermatol Photoimmunol Photomed; 2004 Apr; 20(2):110. PubMed ID: 15030598
    [No Abstract]   [Full Text] [Related]  

  • 16. Open-label study of valacyclovir 1.5 g twice daily for the treatment of uncomplicated herpes zoster in immunocompetent patients 18 years of age or older.
    Madkan VK; Arora A; Babb-Tarbox M; Aboutlabeti S; Tyring S
    J Cutan Med Surg; 2007; 11(3):89-98. PubMed ID: 17511925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-lysine therapy to control the clinical evolution of pityriasis rosea: Clinical case report and literature review.
    Pedrazini MC; Groppo FC
    Dermatol Ther; 2021 Jan; 34(1):e14679. PubMed ID: 33326128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythromycin in pityriasis rosea: A double-blind, placebo-controlled clinical trial.
    Sharma PK; Yadav TP; Gautam RK; Taneja N; Satyanarayana L
    J Am Acad Dermatol; 2000 Feb; 42(2 Pt 1):241-4. PubMed ID: 10642679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster.
    Wood MJ; Johnson RW; McKendrick MW; Taylor J; Mandal BK; Crooks J
    N Engl J Med; 1994 Mar; 330(13):896-900. PubMed ID: 8114860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical presentations of pityriasis rosea: case presentations.
    Chuh A; Zawar V; Lee A
    J Eur Acad Dermatol Venereol; 2005 Jan; 19(1):120-6. PubMed ID: 15649208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.